{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T01:28:13Z","timestamp":1793842093620,"version":"4.6.1"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,8,30]],"date-time":"2026-08-30T00:00:00Z","timestamp":1788048000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,8,30]],"date-time":"2026-08-30T00:00:00Z","timestamp":1788048000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Gastroenterol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Upadacitinib is an oral Janus kinase inhibitor approved for the treatment of moderate-to-severe Crohn\u2019s disease (CD). This post hoc analysis reports the efficacy and safety of upadacitinib for CD in patients in East Asia enrolled in the phase 3 clinical trials.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In two induction studies (U-EXCEL [NCT03345849], U-EXCEED [NCT03345836]), adults with moderately to severely active CD were randomized 2:1 to once-daily upadacitinib 45\u00a0mg or placebo for 12\u00a0weeks. In the 52-week U-ENDURE maintenance study (NCT03345823), patients with clinical response to upadacitinib induction therapy were rerandomized 1:1:1 to once-daily upadacitinib 15\u00a0mg, upadacitinib 30\u00a0mg, or placebo. Data from patients in East Asia were evaluated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In the induction studies, achievement of clinical and endoscopic outcomes occurred at higher rates with upadacitinib vs placebo at week 12 among the 204 patients in East Asia. Clinical remission per CD Activity Index (CDAI) and endoscopic response were achieved by 50.7% vs 20.6% and 61.8% vs 10.3% of patients in the upadacitinib\u00a045-mg vs placebo groups, respectively. Similar trends for upadacitinib vs placebo were observed for the 117 patients in the maintenance study. Clinical remission per CDAI and endoscopic response were achieved by 41.5%, 54.8%, 8.8%, and 28.6%, 45.2%, 5.9% of patients receiving upadacitinib 15\u00a0mg, upadacitinib 30\u00a0mg, and placebo, respectively. The safety profile of upadacitinib was consistent with the global phase 3 population.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Upadacitinib was efficacious in treating moderately to severely active CD among patients in East Asia and demonstrated a favorable benefit\u2013risk profile.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00535-026-02509-y","type":"journal-article","created":{"date-parts":[[2026,8,30]],"date-time":"2026-08-30T07:36:06Z","timestamp":1788075366000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and safety of upadacitinib for Crohn\u2019s disease in patients in East Asia: a post hoc analysis of randomized phase 3 studies"],"prefix":"10.1007","author":[{"given":"Minhu","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiang","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenji","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshimitsu","family":"Fujii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jae Hee","family":"Cheon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shu-Chen","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuh-Ying","family":"Yeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuko","family":"Ishikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick M.","family":"Hecht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Garrison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irina","family":"Fish","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando","family":"Aponte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvio","family":"Danese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2848-6586","authenticated-orcid":false,"given":"Hiroshi","family":"Nakase","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,30]]},"reference":[{"key":"2509_CR1","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1038\/s41572-020-0156-2","volume":"6","author":"G Roda","year":"2020","unstructured":"Roda G, Chien Ng S, Kotze PG, et al. Crohn\u2019s disease. Nat Rev Dis Prim. 2020;6:22.","journal-title":"Nat Rev Dis Prim"},{"key":"2509_CR2","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1016\/S0140-6736(23)02586-2","volume":"403","author":"M Dolinger","year":"2024","unstructured":"Dolinger M, Torres J, Vermeire S. Crohn\u2019s disease. Lancet. 2024;403:1177\u201391.","journal-title":"Lancet"},{"key":"2509_CR3","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1002\/ueg2.12350","volume":"10","author":"S Aniwan","year":"2022","unstructured":"Aniwan S, Santiago P, Loftus EV Jr., et al. The epidemiology of inflammatory bowel disease in Asia and Asian immigrants to Western countries. United Eur Gastroenterol J. 2022;10:1063\u201376.","journal-title":"United Eur Gastroenterol J"},{"key":"2509_CR4","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1038\/s41586-025-08940-0","volume":"642","author":"L Hracs","year":"2025","unstructured":"Hracs L, Windsor JW, Gorospe J, et al. Global evolution of inflammatory bowel disease across epidemiologic stages. Nature. 2025;642:458\u201366.","journal-title":"Nature"},{"key":"2509_CR5","doi-asserted-by":"publisher","first-page":"2769","DOI":"10.1016\/S0140-6736(17)32448-0","volume":"390","author":"SC Ng","year":"2017","unstructured":"Ng SC, Shi HY, Hamidi N, et al. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. Lancet. 2017;390:2769\u201378.","journal-title":"Lancet"},{"key":"2509_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.23922\/jarc.2019-003","volume":"4","author":"S Okabayashi","year":"2020","unstructured":"Okabayashi S, Kobayashi T, Hibi T. Inflammatory bowel disease in Japan-is it similar to or different from Westerns? J Anus Rectum Colon. 2020;4:1\u201313.","journal-title":"J Anus Rectum Colon"},{"key":"2509_CR7","doi-asserted-by":"publisher","first-page":"111","DOI":"10.5217\/ir.2016.14.2.111","volume":"14","author":"WK Ng","year":"2016","unstructured":"Ng WK, Wong SH, Ng SC. Changing epidemiological trends of inflammatory bowel disease in Asia. Intest Res. 2016;14:111\u20139.","journal-title":"Intest Res"},{"key":"2509_CR8","doi-asserted-by":"publisher","first-page":"1658","DOI":"10.1093\/ecco-jcc\/jjab047","volume":"15","author":"D Piovani","year":"2021","unstructured":"Piovani D, Pansieri C, Kotha SRR, et al. Ethnic differences in the smoking-related risk of inflammatory bowel disease: a systematic review and meta-analysis. J Crohns Colitis. 2021;15:1658\u201378.","journal-title":"J Crohns Colitis"},{"key":"2509_CR9","first-page":"1","volume":"5","author":"M-T Weng","year":"2023","unstructured":"Weng M-T, Lin K-L, Huang Y-L, et al. Epidemiology, disease course, and clinical outcomes of perianal fistulas and fissures Crohn\u2019s disease: a nationwide population-based study in Taiwan. Crohn\u2019s & Colitis 360. 2023;5:otad035.","journal-title":"Crohn's & Colitis 360"},{"key":"2509_CR10","doi-asserted-by":"publisher","first-page":"11525","DOI":"10.3748\/wjg.v20.i33.11525","volume":"20","author":"SJ Park","year":"2014","unstructured":"Park SJ, Kim WH, Cheon JH. Clinical characteristics and treatment of inflammatory bowel disease: a comparison of Eastern and Western perspectives. World J Gastroenterol. 2014;20:11525\u201337.","journal-title":"World J Gastroenterol"},{"key":"2509_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/17562848231212089","volume":"16","author":"JWY Mak","year":"2023","unstructured":"Mak JWY, Ho AHY, Ng SC. IBD barriers across the continents - East Asia. Ther Adv Gastroenterol. 2023;16:1\u201311.","journal-title":"Ther Adv Gastroenterol"},{"key":"2509_CR12","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1111\/jgh.15185","volume":"36","author":"Z Ran","year":"2021","unstructured":"Ran Z, Wu K, Matsuoka K, et al. Asian Organization for Crohn\u2019s and Colitis and Asia Pacific Association of Gastroenterology practice recommendations for medical management and monitoring of inflammatory bowel disease in Asia. J Gastroenterol Hepatol. 2021;36:637\u201345.","journal-title":"J Gastroenterol Hepatol"},{"key":"2509_CR13","doi-asserted-by":"publisher","first-page":"285","DOI":"10.5217\/ir.2019.00026","volume":"17","author":"CJ Ooi","year":"2019","unstructured":"Ooi CJ, Hilmi I, Banerjee R, et al. Best practices on immunomodulators and biologic agents for ulcerative colitis and Crohn\u2019s disease in Asia. Intest Res. 2019;17:285\u2013310.","journal-title":"Intest Res"},{"key":"2509_CR14","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/s00535-012-0673-1","volume":"48","author":"F Ueno","year":"2013","unstructured":"Ueno F, Matsui T, Matsumoto T, et al. Evidence-based clinical practice guidelines for Crohn\u2019s disease, integrated with formal consensus of experts in Japan. J Gastroenterol. 2013;48:31\u201372.","journal-title":"J Gastroenterol"},{"key":"2509_CR15","doi-asserted-by":"publisher","first-page":"250","DOI":"10.5217\/ir.2024.00060","volume":"22","author":"JF Wu","year":"2023","unstructured":"Wu JF, Yen HH, Wang HY, et al. Management of Crohn\u2019s disease in Taiwan: consensus guideline of the Taiwan Society of Inflammatory Bowel Disease updated in 2023. Intest Res. 2023;22:250\u201385.","journal-title":"Intest Res"},{"key":"2509_CR16","doi-asserted-by":"publisher","first-page":"43","DOI":"10.5217\/ir.2022.00029","volume":"21","author":"SJ Koh","year":"2023","unstructured":"Koh SJ, Hong SN, Park SK, et al. Korean clinical practice guidelines on biologics for moderate to severe Crohn\u2019s disease. Intest Res. 2023;21:43\u201360.","journal-title":"Intest Res"},{"key":"2509_CR17","doi-asserted-by":"publisher","DOI":"10.1186\/s12876-021-02074-z","volume":"22","author":"J Li","year":"2022","unstructured":"Li J, Liu Z, Hu P, et al. Indicators of suboptimal response to anti-tumor necrosis factor therapy in patients from China with inflammatory bowel disease: results from the EXPLORE study. BMC Gastroenterol. 2022;22:44.","journal-title":"BMC Gastroenterol"},{"key":"2509_CR18","doi-asserted-by":"publisher","first-page":"1966","DOI":"10.1056\/NEJMoa2212728","volume":"388","author":"EV Loftus Jr.","year":"2023","unstructured":"Loftus EV Jr., Pan\u00e9s J, Lacerda AP, et al. Upadacitinib induction and maintenance therapy for Crohn\u2019s disease. N Engl J Med. 2023;388:1966\u201380.","journal-title":"N Engl J Med"},{"key":"2509_CR19","first-page":"1065","volume":"86","author":"KH Li","year":"1991","unstructured":"Li KH, Raghunathan TE, Rubin DB. Large-sample significance levels from multiply imputed data using moment-based statistics and an F reference distribution. J Am Stat Assoc. 1991;86:1065\u201373.","journal-title":"J Am Stat Assoc"},{"key":"2509_CR20","doi-asserted-by":"publisher","DOI":"10.1186\/s12874-017-0404-7","volume":"17","author":"I Eekhout","year":"2017","unstructured":"Eekhout I, van de Wiel MA, Heymans MW. Methods for significance testing of categorical covariates in logistic regression models after multiple imputation: power and applicability analysis. BMC Med Res Methodol. 2017;17:129.","journal-title":"BMC Med Res Methodol"},{"key":"2509_CR21","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11113045","volume":"11","author":"P Wetwittayakhlang","year":"2022","unstructured":"Wetwittayakhlang P, Al Khoury A, Hahn GD, et al. The optimal management of fistulizing Crohn\u2019s disease: evidence beyond randomized clinical trials. J Clin Med. 2022;11:3045.","journal-title":"J Clin Med"},{"key":"2509_CR22","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1241954","volume":"14","author":"Q Xu","year":"2023","unstructured":"Xu Q, He L, Yin Y. Risk of herpes zoster associated with JAK inhibitors in immune-mediated inflammatory diseases: a systematic review and network meta-analysis. Front Pharmacol. 2023;14:1241954.","journal-title":"Front Pharmacol"},{"key":"2509_CR23","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2025-005521","volume":"11","author":"KL Winthrop","year":"2025","unstructured":"Winthrop KL, Klaff J, Penn SK, et al. Immunogenicity of adjuvanted recombinant zoster vaccine in patients with rheumatoid arthritis treated with upadacitinib: 60-week results from a randomised controlled trial substudy. RMD Open. 2025;11:e005521.","journal-title":"RMD Open"},{"key":"2509_CR24","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.1016\/S0140-6736(22)00581-5","volume":"399","author":"S Danese","year":"2022","unstructured":"Danese S, Vermeire S, Zhou W, et al. Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double-blind, randomised trials. Lancet. 2022;399:2113\u201328.","journal-title":"Lancet"}],"container-title":["Journal of Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00535-026-02509-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00535-026-02509-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00535-026-02509-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T01:02:43Z","timestamp":1793840563000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00535-026-02509-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,30]]},"references-count":24,"alternative-id":["2509"],"URL":"https:\/\/doi.org\/10.1007\/s00535-026-02509-y","relation":{},"ISSN":["0944-1174","1435-5922"],"issn-type":[{"value":"0944-1174","type":"print"},{"value":"1435-5922","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,30]]},"assertion":[{"value":"7 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 November 2026","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Supplementary file was missing from this article and has now been uploaded.","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Minhu Chen has received research grants from Janssen and Takeda; has served as an advisory board member for Boehringer Ingelheim and Janssen; and has provided educational activities for AbbVie, China Medical System, IPSEN, Janssen, and Takeda. Xiang Gao has received research grants, served as an advisor, and\/or has supported educational activities for AbbVie, Abbott, Janssen, and Takeda. Kenji Watanabe has received personal fees, has served as a consultant, has served as an advisor, has supported educational activities (including lectures and\/or presentations), has provided expert testimony, and\/or has received support for attending meetings from AbbVie, Bristol Myers Squibb, EA Pharma, Janssen, JIMRO, Kissei, Kyorin, Mitsubishi Tanabe, Mochida, Nippon Kayaku, Pfizer, and Takeda. Toshimitsu Fujii has received speaker\u2019s fees from AbbVie, Boehringer Ingelheim, Bristol Myers Squibb, Daiichi Sankyo, EA Pharma, Eisai, Janssen, Kissei, Kyorin, Kyowa Hakko Kirin, Mitsubishi Tanabe, Mochida, Nichiiko, Nippon Kayaku, Pfizer, Taiho, Takeda, and Zeria; and has received research grants from AbbVie, Alfresa, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, EA Pharma, Eisai, Gilead, Janssen, Kissei, Lilly, Mebix, Sanofi, and Takeda. Jae Hee Cheon has received lecture fees from AbbVie, Celltrion, Eisai, Ferring, Janssen, Pfizer, and Takeda. Shu-Chen Wei has been a consultant or served as an advisory board member for AbbVie, Bristol Myers Squibb, Celltrion, Ferring, Janssen, Pfizer, Spyre, and Takeda; and has received lecture fees from AbbVie, Bristol Myers Squibb, Celltrion, Cornerstones, Excelsior, Ferring, Janssen, Pfizer, Sanofi, Takeda, and ThermoFisher. Yuh-Ying Yeh, Yasuko Ishikawa, Patrick M. Hecht, Andrew Garrison, Irina Fish, and Fernando Aponte are full-time employees of AbbVie, and may hold AbbVie stock and\/or options. Silvio Danese has received consultancy fees from AbbVie, Allergan, Amgen, AstraZeneca, Biogen, Boehringer Ingelheim, Celgene, Celltrion, Enthera, Ferring Pharmaceuticals, Gilead, Hospira, Janssen, Johnson & Johnson, Lilly, Merck Sharp and Dohme, Mundipharma, Mylan, Pfizer, Roche, Sandoz, Sublimity Therapeutics, Takeda, TiGenix, UCB, and Vifor. Hiroshi Nakase has received honoraria from AbbVie, Janssen, Mitsubishi Tanabe, Mylan EPD, Pfizer, and Takeda; has received grants for commissioned\/joint research from AbbVie, AYUMI, HOYA Pentax Medical, Mochida, and Tanabe Mitsubishi; and has received scholarship grants from AbbVie, EA Pharma, Mitsubishi Tanabe, Nippon Kayaku, Otsuka, Taiho, and Takeda.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The Independent Ethics Committee or Institutional Review Board at each study site approved the study protocol, informed consent forms, and recruitment materials before patient enrollment. The studies were conducted in accordance with the International Conference for Harmonisation guidelines, applicable regulations, and the Declaration of Helsinki. All patients provided written informed consent before screening.","order":2,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Written informed consent was obtained from all patients before enrollment.","order":3,"name":"Ethics","label":"Patient consent","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"ClinicalTrials.gov: NCT03345849 (registration first posted 11\/17\/2017), NCT03345836 (registration first posted 11\/17\/2017), NCT03345823 (registration first posted 11\/17\/2017).","order":4,"name":"Ethics","label":"Clinical trial registration","group":{"name":"EthicsHeading","label":"Declarations"}}]}}